Is Retatrutide the King of Fat Loss? Latest News & Study Breakdown
Aug 8, 2025
Discover the latest breakthrough in fat loss with retatrutide, a triple agonist peptide that shows remarkable results in treating type 2 diabetes. The discussion highlights a recent study revealing significant fat loss while preserving muscle mass. Dive into intriguing DEXA scan results and understand how retatrutide compares with other weight loss therapies like semaglutide and tirzepatide. Explore the implications of dosing and why less might be more in this fascinating world of metabolic health.
19:21
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
volunteer_activism ADVICE
Prioritize Muscle During Weight Loss
Prioritize preserving lean mass because muscle is our metabolic currency and supports long-term function.
Hunter Williams cautions against losing weight at the expense of muscle and metabolism.
insights INSIGHT
Triple Agonist Mechanism Explained
Retatrutide agonizes GIP, GLP-1, and glucagon receptors simultaneously.
Hunter Williams says this triple action likely explains its potent weight and metabolic effects.
question_answer ANECDOTE
Trial Placebos And Sponsor Reality
Hunter Williams imagines the emotional letdown for trial participants randomized to placebo.
He also notes the study was funded by Eli Lilly and delivered DEXA-based body composition data.
Get the Snipd Podcast app to discover more snips from this episode
Socials: Instagram: https://www.instagram.com/hunterwilliamscoaching/ Podcast: https://hunterwilliamspodcast.buzzsprout.com/ Video Topic Request: https://hunterwilliamsvideotopic.carrd.co/
Are you ready for the latest retatrutide news? In this video, I (Hunter Williams) dive deep into a brand new phase 2 study on retatrutide—Eli Lilly’s groundbreaking triple agonist peptide for fat loss and metabolic health. I break down the real-world body composition data, including fat loss, muscle loss, visceral fat reduction, and how retatrutide stacks up against other GLP-1 therapies like semaglutide and tirzepatide.
I’ll walk you through the DEXA scan results, discuss the clinical trial design, highlight key numbers (including fat loss index, total lean mass loss, and cardiovascular risk improvements), and share why more is not always better with retatrutide dosing. If you want to know what’s truly happening at the cutting edge of metabolic health—don’t miss this video!
Timestamps
0:00 – Introduction & why today’s retatrutide news matters 1:00 – Study background: Why body composition data is critical 2:08 – What is retatrutide? The triple agonist mechanism explained 3:07 – Retatrutide vs. other GLP-1s: The new study design 4:25 – Clinical trial details (participants, dosing, DEXA scan protocol) 6:24 – Key results: Total fat mass reduction at different doses 7:40 – Surprising findings: Is 8mg the “sweet spot” for fat loss? 8:35 – Total body weight loss vs. placebo and dulaglutide 9:21 – How much muscle do you lose on retatrutide? Lean mass data 10:13 – Visceral fat reduction: Why it matters for long-term health 11:12 – Impact on trunk/leg ratio & cardiovascular risk markers 12:08 – Fat loss index: Proportion of fat vs. muscle lost 13:19 – Retatrutide vs. semaglutide and tirzepatide: Head-to-head data 14:50 – Safety profile & common side effects 15:31 – The role of glucagon receptor agonism & future of peptide therapies 16:38 – Main takeaways: More is not always better with retatrutide 17:41 – Big picture: What’s next for retatrutide and obesity treatment? 18:44 – Final thoughts, feedback, and gratitude
👇 Drop your thoughts and questions below. For more deep dives, subscribe and check out the links in the description—including the peptide cheat sheet and the full study!
The Hunter Williams Podcast